Industry News
Protemix aims to take NZ bio to market
Prof Garth Cooper, CEO of Auckland biopharmaceutical company Protemix Corp, aims to make his company the first New Zealand biotech to take a discovered compound all the way to market. [ + ]
Starpharma losses down, revenues up
Starpharma's (ASX:SPL) 2002-03 revenues jumped 11 per cent to AUD$1.5 million and its operating loss fell to $7.7 million, the company has announced. [ + ]
Vic govt hands $20m to research institutes
Medical research institutes in Victoria have received an 11 per cent increase in state government infrastructure funding, with almost AUD$20 million being distributed between 20 institutes. [ + ]
AGT revenues up, losses down on last year
AGT Biosciences (ASX:AGT) has posted its annual financial results, showing an 11 per cent increase in revenues to $AUD5.2 million, and a loss of $1.9 million down 74.7 per cent from the previous year's loss of $7.5 million. [ + ]
GTG suing Applera, Covance over patent infringement
Melbourne based Genetic Technologies (ASX:GTG) is taking on three of the big guns in the biotechnology industry. [ + ]
Xcell to speed up US push
Xcell Diagnostics (ASX:XEL) will accelerate plans to file for FDA approval of its microDERM video dermatoscope system, following a positive review of its programs by senior management and expert advisors. [ + ]
Biota aims to raise $13m in share purchase plan
Biota (ASX:BTA) is offering shareholders a chance to buy up to AUD$5000 worth of shares at a 10 per cent discount to the market price, the company announced today. [ + ]
Q-Vis to relist on ASX on Thursday
Successful financial surgery on Australian eye-laser developer Q-Vis (ASX:QVL) will see the company reopen its eyes on the Australian Stock Exchange tomorrow, after a successful capital raising of $2.4 million. [ + ]
Genesis to launch Phase II eczema trial in UK
Auckland biopharma Genesis Research and Development Corporation (NSX/ASX:GEN) is to begin a Phase II clinical trial of its AVAC therapy for paediatric atopic dermatitis, or childhood eczema. [ + ]
GTG promises more licensing revenue in coming year
Melbourne biotech Genetic Technologies (ASX:GTG) has released its financial results for 2002-03 financial year, showing a 29 per cent revenue drop to AUD$9.26 million and a net loss of $4.16 million, an improvement over last year's $8.8 million loss. [ + ]
Starpharma raises $6.9m
Pooled investment firm and nanotech specialist Starpharma (ASX:SPL) has raised AUD$6.9 million in an oversubscribed placement to institutional and sophisticated investors. [ + ]
Prana touts development as possible Alzheimer's therapy
Melbourne-based biomedical company Prana Biotechnology (ASX:PBT) has announced it has developed a set of assays for high-throughput testing of molecules with therapeutic potential for Alzheimer's disease. [ + ]
New Austin facility a 'crucial tool'
A new structural biology facility, opened today at the Austin Research Institute, will be a crucial tool in understanding disease processes and will lead to real benefits for the sufferers of cancer, inflammation and other diseases, according to ARI director Prof Mark Hogarth. [ + ]
Peplin blames R&D expenditure for loss
Brisbane cancer-drug developer Peplin Biotech (ASX:PEP) has reported a consolidated loss of AUD$3.7 million for the 12 months to June 30, largely attributable to a big increase in research expenditure on its lead compound, PEP005. [ + ]
Melbourne Centre for Water Research to be established
The University of Melbourne is making an ambitious commitment to water-related research with the establishment of the Melbourne Centre for Water Research.
[ + ]
